Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis

European Urology

Volumn 39, Issue 1, 2001, Pages 57-64

  Lein, Michael ^a   Jung, Klaus ^a   Elgeti, Ulrike ^a   Petras, Tobias ^a   Stephan, Carsten ^a   Brux, Brigitte ^a   Sinha, Pranav ^a   Winkelmann, Björn ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Complexed prostate specific antigen; Prostate specific antigen, free; 1 Antichymotrypsin

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

EID: 17744392612     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052413     Document Type: Article

References (33)

1. Prostate-specific antigen: Current role in diagnostic pathology of prostate cancer
2. Cancer statistics, 2000
3. Practice trends in the diagnosis and management of prostate cancer of prostate cancer
4. Measurement of prostate-specific antigen in serum as screening test for prostate cancer
5. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
6. Clinical utility of measurements of free and total prostate-specific antigen (PSA): A review
7. 1-antichymotrypsin as an indicator of prostate cancer
8. Alpha-1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia
9. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening
10. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: Which cutoff should be used?
11. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples
12. 1-antichymotrypsin
13. Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer
14. 1-antichymotrypsin in plasma
15. 1-antichymotrypsin complex for the screening and management of prostate cancer
16. 1-antichymotrypsin complex
17. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
18. Determination of alpha-1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA
19. 1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia
20. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
21. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy
22. A new biometrical procedure for testing the equality of measurements from two different analytical methods: Application of linear regression procedures for method comparison studies in clinical chemistry. Part 1
23. Software for illustrative presentation of basic clinical characteristics of laboratory tests: GraphROC for Windows
24. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
25. Role of PSA and its indices in determining the need for repeated prostate biopsies
26. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios
27. Measurement of complex between prostate-specific antigen and alpha-protease inhibitor in serum
28. Reference material for PSA: The IFCC standardization study
29. Measurement of complexed PSA improves specificity for early detection of prostate cancer
30. Can complexed PSA be used as a single test for detecting prostate cancer?
31. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay
32. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia